Prader-willi syndrome as a model of human hyperphagia

How Gut and Brain Control Metabolism

Volumn 42, Issue , 2014, Pages 93-106

  Tauber, Maithe ^a,b,c   Diene, Gwenaelle ^a,b   Mimoun, Emmanuelle ^a,b   Çabal Berthoumieu, Sophie ^a,b   Mantoulan, Carine ^a,b   Molinas, Catherine ^a,b,c   Muscatelli, F ^d   Salles, Jean Pierre ^a,b,c  

^a French Reference Centre for Prader Willi Syndrome   (France)

^b HÔPITAL DES ENFANTS   (France)

^c Université Paul Sabatier   (France)

^d Turing Center for Living Systems CENTURI Aix Marseille University   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84925879939     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000358317     Document Type: Chapter

References (26)

1. Prader A, Labhart A, Willi H: Ein Syndrom von Adipositas, Kleinwuchs, Kryptorchidismus und Oligophrenie nach myotoniertigem Zustand im Neugeborenenalter. Schweiz Med Wochenschr 1956; 6: 1260-1261.
2. Goldstone AP, Holland AJ, Hauffa BP, Hokken-Koelega AC, Tauber M: Speakers at the Second Expert Meeting of the Comprehensive Care of Patients with PWS: Recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin Endocrinol Metab 2008; 93: 4183-4197.
3. Miller JL, Lynn CH, Driscoll DC, Goldstone AP, Gold JA, Kimonis V, Dykens E, Butler MG, Shuster JJ, Driscoll DJ: Nutritional phases in Prader-Willi syndrome. Am J Med Genet A 2011; 155A:1040-1049.
4. Holsen LM, Zarcone JR, Brooks WM, Butler MG, Thompson TI, Ahluwalia JS, Nollen NL, Savage CR: Neural mechanisms underlying hyperphagia in Prader-Willi syndrome. Obesity (Silver Spring) 2006; 14: 1028-1037.
5. Feigerlova E, Diene G, Conte-Auriol F, Molinas C, Gennero I, Salles JP, Arnaud C, Tauber M: Hyperghrelinemia precedes obesity in Prader-Willi syndrome. J Clin Endocrinol Metab 2008; 93: 2800-2805.
6. Abizaid A: Ghrelin and dopamine: new insights on the peripheral regulation of appetite. J Neuroendocrinol 2009; 21: 787-793.
7. Olszewski PK, Bomberg EM, Martell A, Grace MK, Levine AS: Intraventricular ghrelin activates oxytocin neurons: implications in feeding behavior. Neuroreport 2007; 18: 499-503.
8. Coiro V, Saccani-Jotti G, Rubino P, Manfredi G, Vacca P, Volta E, Chiodera P: Oxytocin inhibits the stimulatory effect of ghrelin on circulating neuropeptide Y levels in humans. J Neural Transm 2008; 115: 1265-1267.
9. Carneiro BT, Araujo JF: The food-entrainable oscillator: a network of interconnected brain structures entrained by humoral signals? Chronobiol Int 2009; 26: 1273-1289.
10. Steculorum SM, Bouret SG: Developmental effects of ghrelin. Peptides 2011; 32: 2362-2366.
11. Tan TM, Vanderpump M, Khoo B, Patterson M, Ghatei MA, Goldstone AP: Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndrome. J Clin Endocrinol Metab 2004; 89: 4162-4165.
12. Kroemer NB, Krebs L, Kobiella A, Grimm O, Pilhatsch M, Bidlingmaier M, Zimmermann US, Smolka MN: Fasting levels of ghrelin covary with the brain response to food pictures. Addict Biol 2013; 18: 855-862.
13. Berntson GG, Zipf WB, O'Dorisio TM, Hoffman JA, Chance RE: Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndrome. Peptides 1993; 14: 497-503.
14. Swaab DF, Purba JS, Hofman MA: Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases. J Clin Endocrinol Metab 1995; 80: 573-579.
15. Olszewski PK, Klockars A, Schioth HB, Levine AS: Oxytocin as feeding inhibitor: maintaining homeostasis in consummatory behavior. Pharmacol Biochem Behav 2010; 97: 47-54.
16. Schaller F, Watrin F, Sturny R, Massacrier A, Szepetowski P, Muscatelli F: A single postnatal injection of oxytocin rescues the lethal feeding behaviour in mouse newborns deficient for the imprinted Magel2 gene. Hum Mol Genet 2010; 19: 4895-4905.
17. Baskerville TA, Douglas AJ: Dopamine and oxytocin interactions underlying behaviors: potential contributions to behavioral disorders. CNS Neurosci Ther 2010; 16:e92-e123.
18. Febo M: A bold view of the lactating brain: functional magnetic resonance imaging studies of suckling in awake dams. J Neuroendocrinol 2011; 23: 1009-1019.
19. Tauber M, Mantoulan C, Copet P, Jauregui J, Demeer G, Diene G, Roge B, Laurier V, Ehlinger V, Arnaud C, et al: Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: a randomised placebo-controlled trial in 24 patients. Orphanet J Rare Dis 2011; 6: 47.
20. Skryabin BV, Gubar LV, Seeger B, Pfeiffer J, Handel S, Robeck T, Karpova E, Rozhdestvensky TS, Brosius J: Deletion of the MBII-85 snoRNA gene cluster in mice results in postnatal growth retardation. PLoS Genet 2007; 3:e235.
21. Duker AL, Ballif BC, Bawle EV, Person RE, Mahadevan S, Alliman S, Thompson R, Traylor R, Bejjani BA, Shaffer LG, et al: Paternally inherited microdeletion at 15q11.2 confirms a significant role for the SNORD116 C/D box snoRNA cluster in Prader-Willi syndrome. Eur J Hum Genet 2010; 18: 1196-1201.
22. Sahoo T, del Gaudio D, German JR, Shinawi M, Peters SU, Person RE, Garnica A, Cheung SW, Beaudet AL: Prader-Willi phenotype caused by paternal deficiency for the HBII-85 C/D box small nucleolar RNA cluster. Nat Genet 2008; 40: 719-721.
23. De Smith AJ, Purmann C, Walters RG, Ellis RJ, Holder SE, Van Haelst MM, Brady AF, Fairbrother UL, Dattani M, Keogh JM, et al: A deletion of the HBII-85 class of small nucleolar RNAs (snoRNAs) is associated with hyperphagia, obesity and hypogonadism. Hum Mol Genet 2009; 18: 3257-3265.
24. Zhang Q, Bouma GJ, McClellan K, Tobet S: Hypothalamic expression of snoRNA Snord116 is consistent with a link to the hyperphagia and obesity symptoms of Prader-Willi syndrome. Int J Dev Neurosci 2012; 30: 479-485.
25. Powell WT, Coulson RL, Crary FK, Wong SS, Ach RA, Tsang P, Alice Yamada N, Yasui DH, Lasalle JM: A Prader-Willi locus lncRNA cloud modulates diurnal genes and energy expenditure. Hum Mol Genet 2013; 21: 4318-4328.
26. Zhang G, Cai D: Circadian intervention of obesity development via resting-stage feeding manipulation or oxytocin treatment. Am J Physiol Endocrinol Metab 2011; 301:E1004-E1012.